Hymenochirin-1B [E6K]

General Information


DRACP ID  DRACP02300

Peptide Name   Hymenochirin-1B [E6K]

Sequence  IKLSPKTKDNLKKVLKGAIKGAIAVAKMV

Sequence Length  29

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Hymenochirin-1B)

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma LC50=1.2 ± 0.1 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: LC50=186 ± 4 μM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02300

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C140H256N38O35S

Absent amino acids  CEFHQRWY

Common amino acids  K

Mass  356351

Pl  11.28

Basic residues  8

Acidic residues  1

Hydrophobic residues  13

Net charge  7

Boman Index  -1262

Hydrophobicity  15.52

Aliphatic Index  124.48

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24185042

Title  Anti-tumor activities of the host-defense peptide hymenochirin-1B

Doi 10.1016/j.regpep.2013.10.006

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4421

DRACP is developed by Dr.Zheng's team.